SRP4029

Eotaxin from mouse

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)

• Sinónimos: Eosinophil chemotactic protein chemokine (C-C motif) ligand 11, CCL11, SCYA11, Small inducible cytokine A11
• MDL number: MFCD01093488

Propiedades

• biological source: mouse
• recombinant: expressed in E. coli
• assay: ≥98% (HPLC); ≥98% (SDS-PAGE)
• form: lyophilized
• mol wt: ~8.4 kDa
• packaging: pkg of 10 μg
• storage condition: avoid repeated freeze/thaw cycles
• impurities: endotoxin, tested
• NCBI accession no.: P48298
• UniProt accession no.: P48298
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: mouse ... Ccl11(20292)

Descripción

General description

Eotaxin is a member of the CC chemokine family, and belongs to the MCP/eotaxin subfamily. It has a wide range of tissue expression, such as thymus, heart, lungs, lymph nodes, kidney, and intestines. It is also expressed by epithelial cells of lung, pleural mesothelial cells, epithelial cells of bronchial airway, and smooth muscle cells (SMCs).

Biochem/physiol Actions

Eotaxin is a chemoattractant for eosinophils, and is involved inflammatory diseases, such as asthma. It is induced by glucocorticoids and cytokines. Along with interleukin-5 (IL-5) it results in airway hyperresponsiveness (AHR), and hence, lung inflammatory disorders. In humans, it leads to respiratory syncytial virus (RSV) vaccine-enhanced disease, and the eosinophils are also responsible for the elimination of virus. It might also be involved in the pathophysiology of inflammatory bowel diseases which involve eosinophils. It can lead to the production of reactive oxygen species, thus, resulting in damaged tissue. It is overexpressed in multiple diseases such as allergic rhinitis, nasal polyposis, endometriosis and Hodgkin′s disease.

Physical form

Sterile filtered and then lyophilized with no additives. The protein may appear as a haze or film that is difficult to see at the bottom of the vial.

Reconstitution

Reconstitute in water to a concentration of 0.1-1 μg/μL. It is recommended that further dilutions be made into buffer containing carrier protein or medium containing serum.

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Información de seguridad

• RIDADR: NONH for all modes of transport
• WGK Germany: WGK 3
• Flash Point F: Not applicable
• Flash Point C: Not applicable